Learn how VHHs can revolutionize CAR-T cell therapy
Small, stable and robust, VHHs offer an attractive construct for use as targeting agents in cell therapies.
Explore the benefits of VHHs in CAR-T cell therapy and learn how this innovative approach can enhance the effectiveness of next-generation cancer treatments.
Advantages of
VHH in Cell Therapy
Smaller constructs mean more space for multi-specific targeting modules or next-generation signalling domains.
References:
1. Jayaraman J et al. (2020) Ebiomedicine 58: 102931
2. Lamers CH, et al. (2011) Blood 117(1):72-82
3. Ackaert C et al. (2021) Front. Immunol. 12: 632687
4. Desmyter A et al. (1996) Nat Struct Biol 3(9): 803-811
Isogenica’s
VHH in CAR-T Resources
Review: The Application of Nanobody in CAR-T Therapy
Bao et al review the intersection between CAR-T development and VHHs against over a dozen tumour-associated antigens, with a focus on the bi-specific VHH therapy LCAR-B38M, now approved as CARVYKTI™.
VHHs enable multi-specific targeting for Tandem-CAR therapies
In this poster from 7th CAR-TCR Summit in Boston, we discuss the power of VHHs in creating multi-specific ectodomains.
Advantages of using VHH antibodies for CAR engineering
We explain the advantages of VHHs for CAR ectodomain targeting relative to traditional scFvs including size, solubility, and VHHs unique “magic finger” CDR3 domain.
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.